Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

Read original · https://www.prnewswire.com/news-releases/pacira-biosciences-highlights-leading-independent-proxy-advisory-firm-iss-recommendation-to-vote-for-all-of-paciras-director-nominees-302787584.html

Search tags

What matters in this story

Proxy advisory firm ISS has recommended that Pacira stockholders vote against all director nominees proposed by dissident shareholder DOMA Perpetual Capital Management. — ISS recommendations are highly influential for institutional investors, significantly reducing the likelihood of a successful board takeover by the dissident.

+0.60

ISS recommended voting in favor of all three of Pacira's management director nominees. — Validation from a leading proxy advisor supports the current management's strategic direction and stability.

+0.40

ISS reported that Pacira's performance has measurably improved following the launch of its '5x30' strategy for stockholder value creation. — External validation of the company's growth strategy provides positive sentiment regarding future revenue and value targets.

+0.30

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

What matters in this story

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

What matters in this story

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Kuehn Law Encourages Investors of Oracle Corporation to Contact Law Firm

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

What matters in this story

Next reads from the same story arc

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

What matters in this story

Next reads from the same story arc

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Kuehn Law Encourages Investors of Oracle Corporation to Contact Law Firm